CatalYm

Catalyzing Immunotherapy

Planegg-Martinsried, Germany · Founded 2016 · $216.0M raised

Founded
2016
Business Model
B2B
Total Funding
$216.0M
Last Round
$150.0M Series DJul 2024
Rounds
2

About

CatalYm is a clinical-stage biotech company focused on neutralizing GDF-15, a key cancer immunosuppressant hijacked by tumors to evade immune attack. Its lead antibody visugromab has demonstrated durable anti-tumor efficacy in combination with anti-PD-1 in relapsed and refractory metastatic solid tumor patients. Founded in 2016, CatalYm is headquartered in Planegg-Martinsried (Munich), Germany, and advancing visugromab into Phase 2b studies.

Summary

CatalYm is a Biotech company based in Planegg-Martinsried, Germany, founded in 2016. It has raised $216.0M in total across 2 rounds, most recently a $150.0M Series D round in Jul 2024. Investors include Canaan Partners, Bioqube Ventures and Forbion Growth Opportunities Fund.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series DSeries DJul 2024
$150.0M

Sign up to see all 2 rounds

Series B through Series D — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

CatalYm on Indexed.vc
<a href="https://indexed.vc/companies/catalym"><img src="https://indexed.vc/api/badge/company/catalym" alt="CatalYm on Indexed.vc" width="260" height="76" /></a>